Target intelligence / Profile preview

Intercellular adhesion molecule 5 (ICAM5)

Target
ICAM5
Molecular classification
Adhesion molecule, Immunoglobulin superfamily (IgSF), Cell surface glycoprotein
01

Overview

Intercellular adhesion molecule 5 (ICAM5), also known as telencephalin, is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It has nine extracellular Ig-like domains and is expressed exclusively in telencephalic neurons of the brain. ICAM5 plays critical roles in neuronal cell adhesion, dendritic growth, and synaptic formation. It mediates both homophilic (neuron-neuron) and heterophilic (neuron-leukocyte via LFA-1) adhesion, facilitating neuron-microglial interactions that are important for brain development and immune regulation. Its developmental regulation is linked with dendritic maturation and synapse plasticity. ICAM5 may help maintain immune privilege in the CNS, suppressing inflammatory responses and limiting neuronal damage. Alterations in ICAM5 expression or function are implicated in neurodevelopmental disorders, and variants in its gene may elevate risk for certain cancers.

Other names
TelencephalinTLCNTLNICAM-5intercellular adhesion molecule 5ICAM5
02

Mechanism of action

Not directly targeted by drugs, but mechanistically, ICAM5 functions by binding to LFA-1 (integrin αLβ2) on leukocytes to modulate cell adhesion and immune responses in the CNS

03

Biological functions

Neuronal cell adhesion (somatodendrite-specific)Immune-nervous system interactionsRegulation of dendritic morphology and synapse formationModulation of T cell activation and immune privilege in the brainPossible roles in cognition and dendritic plasticity
04

Disease associations

Neurodegenerative diseases (potential dysregulation in conditions affecting brain development and function)Cancer (breast cancer risk associated with specific ICAM5 gene polymorphisms)Neuroinflammation (ICAM5 interaction with immune cells and role in limiting inflammatory damage in brain tissue)
05

Safety considerations

No known specific toxicity or adverse event profile, as it is not a current drug target.Potential challenges in targeting ICAM5 may include risk of altering cognitive function or synaptic development if broadly modulated
06

Interacting drugs

No specific drugs currently approved or widely recognized to directly target ICAM5
07

Biomarkers

ICAM5 polymorphisms (e.g., rs1056538, rs281439) may serve as biomarkers for breast cancer riskPotential biomarker for neuronal health or neuroinflammation, though not widely validated

Beyond the preview

Go deeper on Intercellular adhesion molecule 5 (ICAM5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intercellular adhesion molecule 5 (ICAM5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call